The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Open accessAbstract
Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [32]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [32]
In the citing paper
“The study compared docetaxel with ramucirumab or placebo in patients who had progressed after platinum-based chemotherapy.Median OS was longer (10.5 versus 9.1 months, HR 0.86, 95% CI: 0.75-0.98,P = 0.023) in the ramucirumab arm compared with the placebo arm.Median PFS was also superior in the ramucirumab arm”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [94]
In the citing paper
“One trial tested a new vascular endothelial growth factor inhibitor for NSCLC, ramucirumab (plus docetaxel); the intervention arm experienced longer PFS (by 1.5 months) and OS (by 1.4 months), both statistically significant.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [57]
In the citing paper
“Hematologic adverse events were more frequent with ramucirumab plus docetaxel, as were other adverse events, such as diarrhea, dyspnea, and fatigue.57”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [57]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citationJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948
Research works printed but not linked: 1
- Wilke, 2014, J Clin Oncol, 32
Cited by
Sorted by citations
Items 401–500 of 1,001
Nakamura, A., Yamaguchi, O., Mori, K. P., Miura, K., Tamiya, M., Oba, T., Yanagitani, N., Mizutani, H., Ninomiya, T., Kajiwara, T., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.025 · Cited by 23
Elkrief, A., Odintsov, I., Markov, V., Caeser, R., Sobczuk, P., Tischfield, S. E., Bhanot, U. K., Vanderbilt, C., Cheng, E. H., Drilon, A. E. D. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.007 · Cited by 23
Vokes, E. E., Mornex, F., Sezer, A., Cheng, Y., Fang, J., Baz, D. V., Çil, T., Adjei, A. A., Ahn, M., Barlési, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1452 · Cited by 21
Self-citationBondarenko, I. M., Ingrosso, A., Bycott, P. W., Kim, S., & Cebotaru, C. L. (2015) · BMC Cancer · doi:10.1186/s12885-015-1350-6 · Cited by 21
Chemotherapy for Advanced Non-small Cell Lung Cancer
Dietrich, M. F., & Gerber, D. E. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_6 · Cited by 22
Targeted Therapies for Lung Cancer
Stinchcombe, T. E. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_8 · Cited by 22
Pharmacological cancer treatment and venous thromboembolism risk
Martín, A. J. M., Ramírez, S. P., Morán, L. O., Zamorano, M. R., Viñuela-Benéitez, M. C., Aparicio, I., Escobar, I. G., & Soria, J. M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa004 · Cited by 21
Wang, H., Chu, J., Zhao, Y., Tang, H., Wang, L., Zhou, M.-Q., Yan, Z., Liu, Y., & Yao, Z. (2020) · Cancer Management and Research · doi:10.2147/cmar.s249678 · Cited by 21
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib
Santos, E. S., & Hart, L. L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s250446 · Cited by 22
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Sundar, R., Chénard-Poirier, M., Collins, D. C., & Yap, T. A. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00039 · Cited by 22
Protopapa, M., Kouloulias, V., Nikoloudi, S., PAPADIMITRIOU, C. A., Gogalis, G., & Zygogianni, A. G. (2019) · Journal of Oncology · doi:10.1155/2019/3267409 · Cited by 21
Zhang, M., Zhu, J., Bao, Y., Ao, Q., Mao, X., Qiu, Z., Zhang, Y., Chen, Y., Zhu, H., & Gao, J. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1589841 · Cited by 20
Daaboul, N., Nicholas, G. A., & Laurie, S. A. (2018) · Current Oncology · doi:10.3747/co.25.3792 · Cited by 20
Miyawaki, E., Kenmotsu, H., Shintani, Y., Sekine, I., Shukuya, T., Takayama, K., Inoue, A., Okamoto, I., Kiura, K., Takahashi, K., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09441-3 · Cited by 21
Yoo, C., Lamarca, Á., Choi, H. J., Vogel, A., Pishvaian, M. J., Goyal, L., Ueno, M., Märten, A., Teufel, M., Geng, L., et al. (2024) · Future Oncology · doi:10.2217/fon-2023-0963 · Cited by 21
Wang, Z., Zhang, J., Zhang, L., Liu, P., Xie, Y., & Zhou, Q. (2015) · Journal of Chemotherapy · doi:10.1179/1973947815y.0000000053 · Cited by 20
Park, K., Kim, J.-H., Cho, E. K., Kang, J. H., Shih, J., Zimmermann, A. H., Lee, P., Alexandris, E., Puri, T., & Orlando, M. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.401 · Cited by 20
Self-citationZhang, X., Zhang, D., & Zhao, C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s103735 · Cited by 20
Barnfield, P. C., & Ellis, P. M. (2016) · Drugs · doi:10.1007/s40265-016-0628-6 · Cited by 20
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016
Bunn, P. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4064 · Cited by 20
Paz-Ares, L. G., Pérol, M., Ciuleanu, T., Kowalyszyn, R. D., Reck, M., Lewanski, C. R., Syrigos, K., Arrieta, O. G., Prabhash, K., Park, K., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.021 · Cited by 20
Self-citationSurvivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas
Sumi, T., Hirai, S., Yamaguchi, M., Tanaka, Y., Tada, M., Yamada, G., Hasegawa, T., Miyagi, Y., Niki, T., Watanabe, A., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4365 · Cited by 20
Zhou, S., Zuo, L., He, X., Pi, J., Jin, J., & Shi, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12827 · Cited by 20
Goss, G. D., Cobo, M., Lü, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Isla, D., Morabito, A., Min, Y. J., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100940 · Cited by 21
Self-citationThe safety of ramucirumab for the treatment of colorectal cancer
Noguerido, A., Mulet-Margalef, N., Matos, I. G., Ros, J., Argilés, G., Élez, E., & Tabernero, J. M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1506762 · Cited by 20
Management of Lung Cancer in the Elderly
Rao, A., Sharma, N., & Gajra, A. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_12 · Cited by 20
Spigel, D. R., Luft, A. V., Depenbrock, H., Ramlau, R., Khalil, M. Y., Kim, J.-H., Mayo, C., Chao, G. Y., Obasaju, C. K., & Natale, R. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.02.002 · Cited by 19
Self-citationPredictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients
Sone, K., Oguri, T., Ito, K., Kitamura, Y., INOUE, Y., TAKEUCHI, A., Fukuda, S., TAKAKUWA, O., Maeno, K., Asano, T., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11932 · Cited by 19
Nixon, A. B., Sibley, A. B., Liu, Y., Hatch, A. J., Jiang, C., Mulkey, F., Starr, M. D., Brady, J. C., Niedzwiecki, D., Venook, A. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2389 · Cited by 20
Zhang, Y., Song, L., Zeng, L., Xiong, Y., Liu, L., Zhou, C., Yang, H., Wang, Z., Xia, Q., Jiang, W., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10045-0 · Cited by 19
Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer
Kaur, P., Singh, S. K., Mishra, M. K., Singh, S., & Singh, R. (2024) · Cancers · doi:10.3390/cancers16122205 · Cited by 19
Hetta, . F., Aljohani, H. M., Sirag, N., Elfadil, H., Salama, A., Al-Twalhy, R., Alanazi, D. A., Aljohani, M. M., Albalawi, J. H., Al-Otaibi, R. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040585 · Cited by 19
Management of Dermatologic Complications of Lung Cancer Therapies
Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0368-y · Cited by 19
Abdel-Rahman, O. M., & Elhalawani, H. M. (2014) · Chemotherapy · doi:10.1159/000437253 · Cited by 19
Wang, J., Wang, Z., & Zhao, Y. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0272-z · Cited by 19
Reck, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1031218 · Cited by 19
Self-citationSyrios, J., Nintos, G., & Georgoulias, V. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1069186 · Cited by 19
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer
Buttigliero, C., Bertaglia, V., & Novello, S. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.09.03 · Cited by 18
Wang, L., Cao, Y., Ren, M., Chen, A., Cui, J., Sun, D., & Gu, W. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.008 · Cited by 19
Corrales, L., Nogueira, A., Passiglia, F., Listì, A., Caglevic, C., Giallombardo, M., Raez, L. E., Santos, E. S., & Rolfo, C. D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00013 · Cited by 21
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19
Hyperprogression with immunotherapy: Is it real?
Popat, S. (2019) · Cancer · doi:10.1002/cncr.31997 · Cited by 18
Li, T., Piperdi, B., Walsh, W. V., Kim, M., Beckett, L. A., Gucalp, R. A., Haigentz, M., Bathini, V. G., Wen, H., Zhou, K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.003 · Cited by 18
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
Le, A., Alzghari, S. K., Jean, G. W., & La-Beck, N. M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s104343 · Cited by 18
Clinical Versus Statistical Significance in Studies of Thoracic Malignancies
Dahlberg, S. E., Korn, E. L., Le‐Rademacher, J. G., & Mandrekar, S. J. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.007 · Cited by 18
Friedes, C., Mai, N., Fu, W., Hu, C., Hazell, S. Z., Han, P., McNutt, T., Forde, P. M., Redmond, K. J., Voong, K. R., et al. (2020) · Cancer · doi:10.1002/cncr.33109 · Cited by 19
Grohé, C., Blau, W. J., Gleiber, W., Haas, S., Hammerschmidt, S., Krüger, S., Müller-Huesmann, H., Schulze, M., Wehler, T., Atz, J., et al. (2022) · Clinical Oncology · doi:10.1016/j.clon.2021.12.010 · Cited by 18
αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade
Pan, M., Wang, F., Nan, L., Yang, S., Qi, J., Xie, J., Shao, S., zou, H., Wang, M., Sun, F., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03306-1 · Cited by 18
Personalized treatment for patients with lung cancer
Schüler, M., Bölükbas, S., Darwiche, K., Theegarten, D., Herrmann, K., & Stuschke, M. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0012 · Cited by 20
Pragmaticism in Cancer Clinical Trials
Sankar, K. N., Redman, M. W., Dragnev, K. H., Henick, B. S., Iams, W. T., Blanke, C. D., Herbst, R. S., Gray, J. E., & Reckamp, K. L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100040 · Cited by 19
Abdel-Rahman, O. M., & Elhalawani, H. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.003 · Cited by 18
Popat, S., Mellemgaard, A., Reck, M., Hastedt, C., & Griebsch, I. (2017) · Future Oncology · doi:10.2217/fon-2016-0493 · Cited by 18
Self-citationAnti-VEGF Therapy in Cancer: A Double-Edged Sword
Gardner, V., Madu, C. O., & Lu, Y. W. (2017) · InTech eBooks · doi:10.5772/66763 · Cited by 20
Cost analysis of adverse events associated with non-small cell lung cancer management in France
CHOUAID, C., Loirat, D., Clay, E., Millier, A., Godard, C., Fannan, A., Lévy-Bachelot, L., & Angevin, E. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s138963 · Cited by 18
Zhao, S., Zhang, Z., Zhang, Y., Hong, S., Zhou, T., Yang, Y., Fang, W., Zhao, H., & Zhang, L. (2018) · International Journal of Cancer · doi:10.1002/ijc.31995 · Cited by 18
Zheng, J.-C., Chang, K., Jin, Y., Zhao, X., Li, B., & Yang, M. (2019) · Medical Science Monitor · doi:10.12659/msm.913091 · Cited by 18
RetractedHsu, P., Huang, C.-Y., Wang, C., Kuo, C. S., Chu, C., Tung, P., Huang, A. C., Wang, C., Chiu, L., Fang, Y., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13110331 · Cited by 18
Zhong, Q., & Liu, Z. (2021) · Cancer Management and Research · doi:10.2147/cmar.s304838 · Cited by 18
Combination therapy patents: a new front in evergreening
Strohbehn, G. W., Kacew, A. J., Goldstein, D. A., Feldman, R., & Ratain, M. J. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01137-6 · Cited by 18
Cortinovis, D. L., Gregorc, V., Migliorino, M. R., Abbate, M. I., Manzo, A., Malapelle, U., & Morabito, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.015 · Cited by 17
Garon, E. B., Visseren‐Grul, C., Rizzo, M. T., Puri, T., Chenji, S., & Reck, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1247879 · Cited by 17
Self-citationNishino, K., Imamura, F., Kumagai, T., Katakami, N., Hata, A., Okuda, C., Urata, Y., Hattori, Y., TACHIHARA, M. Y., Yokota, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.022 · Cited by 19
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
Zhang, Y., Yao, K., Shi, C., Jiang, Y., Liu, K., Zhao, S., Chen, H., Reddy, K., Zhang, C., Chang, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6236 · Cited by 17
The Value of PD-L1 Testing in Non–Small-Cell Lung Cancer
Lisberg, A. E., & Garon, E. B. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0043 · Cited by 17
Self-citationReck, M., Garon, E. B., Paz-Ares, L. G., Ponce, S., Jaime, J. C., Juan, Ó., Nadal, E., Kiura, K., Widau, R. C., He, S., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.11.003 · Cited by 17
Self-citationCombined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy
Li, W., Xue, J., & Xu, H. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s189864 · Cited by 17
Isla, D., de Castro, J., García‐Campelo, R., LIANES, P., Felip, E., Garrido, P., Paz-Ares, L. G., & Trigo, J. M. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02191-y · Cited by 17
Guo, M., Liu, Z., Si, J., Zhang, J., Zhao, J., Guo, Z., Xie, Y., Zhang, H., & Gan, L. (2021) · BioMed Research International · doi:10.1155/2021/5582648 · Cited by 17
Recent Advances in Lung Cancer Therapy Based on Nanomaterials: A Review
Gholami, L., Ivari, J. R., Nasab, N. K., Oskuee, R. K., Sathyapalan, T., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210810160901 · Cited by 18
Matsumoto, K., Shiroyama, T., Kuge, T., Miyake, K., Yamamoto, Y., Yoneda, M., Yamamoto, M., Naito, Y., Suga, Y., Fukushima, K., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.008 · Cited by 17
Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Melosky, B. L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00038 · Cited by 18
Ramucirumab (Cyramza): A Breakthrough Treatment for Gastric Cancer.
Singh, A. D., & Parmar, S. (2015) · PubMed Central · Cited by 17
Ozawa, Y., Akahori, D., Koda, K., Abe, T., Hasegawa, H., Matsui, T., Tanahashi, M., Niwa, H., Yamada, K., Yokomura, K., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3025-7 · Cited by 17
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
Vavalà, T. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s112715 · Cited by 19
Newly developed anti-angiogenic therapy in non-small cell lung cancer
Qu, J., Zhang, Y., Chen, X., Yang, H., Zhou, C., & Yang, N. (2017) · Oncotarget · doi:10.18632/oncotarget.23755 · Cited by 17
Weiss, J. M., Pennell, N. A., Deal, A. M., Morgensztern, D., Bradford, D. S., Crane, J. M., West, H., Lee, C. B., Pecot, C. V., Stevenson, J. P., et al. (2020) · Cancer · doi:10.1002/cncr.32573 · Cited by 17
Bilger, G., Toffart, A.-C., Darrason, M., Duruisseaux, M., Ulmer, L., Wang, P., Leprieur, E. G., Girard, N., Massiani, M. A., Bore, P., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221099399 · Cited by 15
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 17
Rolfo, C. D., Hess, L. M., Jen, M., Peterson, P. M., Li, X., Liu, H., Lai, Y., Sugihara, T., Kiiskinen, U., Vickers, A. D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100551 · Cited by 16
Herzog, B. H., Waqar, S. N., Devarakonda, S. H. K., Ward, J. P., Gao, F., Govindan, R., & Morgensztern, D. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.09.011 · Cited by 17
Sahu, P., Donovan, C., Paudel, K. R., Pickles, S., Chimankar, V., Kim, R., Horvart, J. C., Dua, K., Ieni, A., Nucera, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1260411 · Cited by 16
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 16
Yu, J., Jin, F., Zhu, H., Shi, F., & Kong, L. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s97363 · Cited by 16
Grabowski, J., & Glode, A. E. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150188 · Cited by 16
Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer
Durm, G. A., & Hanna, N. H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.002 · Cited by 16
Aggarwal, C., & Borghaei, H. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0345 · Cited by 16
Stewart, D. J., Bossé, D., Goss, G. D., Hilton, J. F., Jonker, D. J., & Fung‐Kee‐Fung, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102896 · Cited by 16
Effing, S. M. A., & Gyawali, B. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100458 · Cited by 16
Molecular Mechanisms of Resistance to Anti-Angiogenic Drugs
Filippelli, A., Ciccone, V., Donnini, S., Ziche, M., & Morbidelli, L. (2020) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2020035422 · Cited by 16
Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells
Yang, R., Shen, S., Gong, C. L., Wang, X., Luo, F., Luo, F., Lei, Y., Wang, Z., Xu, S.-S., Ni, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654080 · Cited by 16
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Лактионов, К. К., Артамонова, Е. В., Borisova, T. N., Владимирович, Б. В., Маркович, Б. Ю., Vladimirova, L. Y., Volkov, N., Ергнян, С. М., Zhabina, A. S., Kononets, P. V., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.3.201048 · Cited by 19
A pharmacological exploration of targeted drug therapy in non-small cell lung cancer
Jayan, A. P., Anandu, K. R., Madhu, K., & Nirmala, S. V. (2022) · Medical Oncology · doi:10.1007/s12032-022-01744-6 · Cited by 16
Master protocols in lung cancer: experience from Lung Master Protocol
Lam, V. K. L., & Papadimitrakopoulou, V. A. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000433 · Cited by 16
Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
Lee, H. J., Moon, J. Y., & Baek, S. W. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.8663 · Cited by 16
Emerging drugs for squamous cell lung cancer
Cheng, H., Shcherba, M., Kandavelou, K., Liang, Y., Liu, H., & Perez-Soler, R. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1001365 · Cited by 15
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
Soo, R. A., Ang, Y. L. E., & Lim, J. S. J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s84356 · Cited by 15
Cohen, J. T., Lin, P., Sheinson, D. M., Wong, W. B., Wu, N., Yim, Y. M., & Ramsey, S. D. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00241 · Cited by 15
Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes
Zhang, C., Li, M., Lin, Y., & Gao, Q. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200628014530 · Cited by 15
Matsumoto, K., Tamiya, A., Matsuda, Y., Taniguchi, Y., Atagi, S., Kawachi, H., Tamiya, M., Tanizaki, S., Uchida, J., Ueno, K., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1263 · Cited by 14
Sonoda, T., Umeda, Y., Demura, Y., Tada, T., Nakashima, K., Anzai, M., Yamaguchi, M., Shimada, A., Ohi, M., Honjo, C., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5978 · Cited by 14
Metadata
- Authors
- Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
- Affiliations
- University of California, Los Angeles (US)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Instituto Nacional de Cancerología (MX)
- Tata Memorial Hospital (IN)
- Sotiria General Hospital (GR)
- Samsung Medical Center (KR)
- Russian Cancer Research Center NN Blokhin (RU)
- Charing Cross Hospital (GB)
- University Hospital Heidelberg (DE)
- Azienda Ospedaliera San Gerardo (IT)
- Cancer Center of Kansas (US)
- Gemeinschaftskrankenhaus Herdecke (DE)
- Yonsei University Health System (KR)
- Institutul Oncologic Bucuresti (RO)
- City Clinical Oncology Center (RU)
- German Center for Lung Research (DE)
- Ospedale di Livorno (IT)
- Eli Lilly (United States) (US)
- Corresponding author
- Garon, Edward B
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 384
- Issue
- 9944
- Pages
- 665-673
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2140980839
- Cited by
- 1,309
- References
- 35
- Citations by year
- 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
- FWCI
- 116.89
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
- MeSH terms
- Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
